Acurx Pharmaceuticals (ACXP) Competitors $0.43 0.00 (-0.14%) As of 10:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACXP vs. PLUR, PRLD, MURA, ATNM, SCLX, GRCE, XCUR, ACRV, PEPG, and STTKShould you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Pluri (PLUR), Prelude Therapeutics (PRLD), Mural Oncology (MURA), Actinium Pharmaceuticals (ATNM), Scilex (SCLX), Grace Therapeutics (GRCE), Exicure (XCUR), Acrivon Therapeutics (ACRV), PepGen (PEPG), and Shattuck Labs (STTK). These companies are all part of the "pharmaceutical products" industry. Acurx Pharmaceuticals vs. Its Competitors Pluri Prelude Therapeutics Mural Oncology Actinium Pharmaceuticals Scilex Grace Therapeutics Exicure Acrivon Therapeutics PepGen Shattuck Labs Pluri (NASDAQ:PLUR) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk. Does the media refer more to PLUR or ACXP? In the previous week, Acurx Pharmaceuticals had 1 more articles in the media than Pluri. MarketBeat recorded 2 mentions for Acurx Pharmaceuticals and 1 mentions for Pluri. Acurx Pharmaceuticals' average media sentiment score of 0.94 beat Pluri's score of 0.93 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Pluri Positive Acurx Pharmaceuticals Positive Do analysts rate PLUR or ACXP? Pluri presently has a consensus price target of $12.00, indicating a potential upside of 139.76%. Acurx Pharmaceuticals has a consensus price target of $8.00, indicating a potential upside of 1,747.58%. Given Acurx Pharmaceuticals' higher possible upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PLUR or ACXP more profitable? Acurx Pharmaceuticals has a net margin of 0.00% compared to Pluri's net margin of -2,563.29%. Acurx Pharmaceuticals' return on equity of -526.78% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Pluri-2,563.29% -4,191.91% -85.40% Acurx Pharmaceuticals N/A -526.78%-223.78% Which has more volatility & risk, PLUR or ACXP? Pluri has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -1.23, suggesting that its share price is 223% less volatile than the S&P 500. Which has preferable valuation and earnings, PLUR or ACXP? Acurx Pharmaceuticals has lower revenue, but higher earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPluri$330K119.36-$20.89M-$5.53-0.91Acurx PharmaceuticalsN/AN/A-$14.10M-$0.70-0.62 Do institutionals & insiders believe in PLUR or ACXP? 16.6% of Pluri shares are owned by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. 25.9% of Pluri shares are owned by company insiders. Comparatively, 26.0% of Acurx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryAcurx Pharmaceuticals beats Pluri on 9 of the 13 factors compared between the two stocks. Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACXP vs. The Competition Export to ExcelMetricAcurx PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.71M$2.92B$5.56B$9.28BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-0.6220.3128.6419.62Price / SalesN/A299.14430.8295.68Price / CashN/A43.1536.0257.93Price / Book14.437.658.155.59Net Income-$14.10M-$55.11M$3.24B$257.73M7 Day Performance-13.40%-0.23%-0.64%-0.23%1 Month Performance41.00%7.20%4.92%7.98%1 Year Performance-82.47%-3.60%25.99%13.16% Acurx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACXPAcurx Pharmaceuticals2.565 of 5 stars$0.43-0.1%$8.00+1,747.6%-81.9%$12.71MN/A-0.623Gap UpPLURPluri3.2875 of 5 stars$5.79+0.2%$12.00+107.3%-6.4%$45.28M$330K-1.05150Gap DownPRLDPrelude Therapeutics3.6795 of 5 stars$0.81+1.6%$4.50+457.8%-85.6%$44.82M$7M-0.48120Gap DownMURAMural Oncology3.1637 of 5 stars$2.48-3.9%$12.00+383.9%-24.8%$44.55MN/A-0.32119ATNMActinium Pharmaceuticals2.803 of 5 stars$1.42-1.4%$4.00+181.7%N/A$44.30MN/A-1.0230Positive NewsGap UpSCLXScilex2.5455 of 5 stars$6.25-1.7%$455.00+7,180.0%-89.8%$44.21M$50.71M-0.2280Positive NewsGRCEGrace Therapeutics2.5484 of 5 stars$3.00-4.2%$12.00+300.0%N/A$43.28MN/A-3.37N/APositive NewsXCURExicure1.3319 of 5 stars$6.47-4.6%N/A+1,999.3%$42.83M$500K-1.6950Positive NewsGap UpACRVAcrivon Therapeutics3.7354 of 5 stars$1.25-3.1%$17.71+1,317.1%-82.9%$40.45MN/A-0.5658Positive NewsPEPGPepGen3.079 of 5 stars$1.11-9.0%$7.67+590.7%-92.5%$39.92MN/A-0.3530STTKShattuck Labs3.7173 of 5 stars$0.77-7.4%$7.50+871.5%-82.8%$39.92M$5.72M-0.56100News CoveragePositive News Related Companies and Tools Related Companies Pluri Alternatives Prelude Therapeutics Alternatives Mural Oncology Alternatives Actinium Pharmaceuticals Alternatives Scilex Alternatives Grace Therapeutics Alternatives Exicure Alternatives Acrivon Therapeutics Alternatives PepGen Alternatives Shattuck Labs Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACXP) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
